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Conclusions: In contrast to the effects of either substanceEffects of enalapril and eprosartan on the renal vascular nitric
alone, a combination of half the dose of eprosartan with halfoxide system in human essential hypertension.
the dose of enalapril had a prominent effect on renal perfusion.Background: Experimental data in humans on the contribu-
The effects of eprosartan on RPF are mediated, at least intion of angiotensin-converting enzyme inhibitors and angioten-
part, by an increased bioavailability of nitric oxide in the renalsin II type 1 receptor blockers to the nitric oxide system of the
vasculature.renal vasculature are inconsistent. Enalapril and eprosartan,
alone and in combination, were used to determine their short-
term effects on the renal nitric oxide system and renal hemody-
namics of human subjects with essential hypertension. Angiotensin-converting enzyme inhibitors (ACEI)Methods: Twenty male, white patients (27  1 years) with
and angiotensin II type 1 receptor blockers (ARB) havemild essential hypertension (143  11/95  6 mm Hg) were
been found to preserve renal function in various clinicalincluded in a double-blind, randomized, placebo-controlled,
fourfold cross-over study with placebo, enalapril (20 mg/day), conditions [1]. Both classes of agents inhibit the vasocon-
eprosartan (600 mg/day), or combination of both drugs (10 strictive effects of angiotensin II at the efferent arteriole
and 300 mg/day, respectively) each over a one week period either by reducing the concentration of angiotensin IIfollowed by a two-week washout phase. After each study phase
(in the case of ACEI) or by blocking its receptor (in thethe glomerular filtration rate (GFR) and renal plasma flow
case of ARB). This specific site of action explains in part(RPF) were determined. Basal nitric oxide synthesis of the
renal vasculature was assessed by the decrease in RPF after why ACEI and ARB have superior “nephroprotective”
inhibition of nitric oxide synthase with NG-monomethyl-l-argi- properties compared to other antihypertensive drugs.
nine (L-NMMA; 4.25 mg/kg). However, apart from reducing blood pressure and glo-Results: After one week of therapy, the combination therapy
merular hypertension, other intrarenal actions such asdecreased casual blood pressure by 5  2/3  1 mm Hg versus
improving endothelial function in the renal vasculatureplacebo (P  0.01). Neither enalapril alone (2  2/1  2
mm Hg, NS vs. placebo) nor eprosartan alone (1  1/0  2 are thought to contribute to the effects of ACEI and
mm Hg, NS vs. placebo) had a clear-cut significant effect on ARB in the kidney [2].
casual blood pressure. In the combination phase, RPF in- Treatment with ACEI increases the level of bradykinin,creased by 123  36 mL/min (P  0.01). Neither enalapril
which is degraded by angiotensin-converting enzyme. Bra-alone (59  46 mL/min, P  0.21) nor eprosartan alone
dykinin stimulates nitric oxide synthesis. Consequently,(113 51 mL/min, P 0.06) had a clear-cut significant effect
on RPF. Changes of RPF induced by treatment correlated with ACEI have been found to increase nitric oxide produc-
the L-NMMA induced decrease in RPF in the combination tion in vitro and in various vasculatures, particularly in
(r  0.70, P  0.01) and eprosartan phase (r  0.86, P  the coronary vasculature [3]. Blockade of the angiotensin0.001), but not in the enalapril phase (r  0.44, P  0.10).
II type 1 (AT1) receptor with an ARB causes increasedRenal vascular resistance was reduced by each active treatment
stimulation of the AT2-receptor by angiotensin II whosewith the most prominent reduction in the combination phase.
GFR was unaffected by any treatment. concentrations are elevated due to the ARB medication
[4]. Stimulation of nitric oxide synthesis via AT2-receptor
stimulation has been found in rats [5] and is believed to
1 See Editorial by Noris and Remuzzi, p. 1545. play a role in nephroprotection in humans, too [6].
On the basis of these studies, it was reasonable toKey words: endothelium, nitric oxide, kidney, angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers. assume that therapy with ACEI and ARB combined
might have additive effects on nitric oxide bioavailabilityReceived for publication June 13, 2001
due to their different sites of action. In fact, combinationand in revised form October 1, 2001
Accepted for publication November 2, 2001 therapy with both an ACEI and an ARB was found to
increase cardiac output and ejection fraction in patients 2002 by the International Society of Nephrology
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Table 1. Baseline clinical parameterswith heart failure [7, 8] and to reduce proteinuria in
patients with glomerulonephropathy (abstract; Russo D, Age years 271
Weight kg 822J Am Soc Nephrol 11:76A, 2000; abstract; Kincaid-Smith
Height m 1.830.02PS, J Am Soc Nephrol 11:349A, 2000). Body surface area m2 2.040.04
However, experimental data in humans concerning Body mass index kg/m2 24.30.5
Casual systolic blood pressure mm Hg 14311the contribution of the nitric oxide system of the renal
Casual diastolic blood pressure mm Hg 956vasculature to the renal effects of ACEI and ARB are Urinary sodium excretion mmol/day 22369
inconsistent. Some investigators failed to observe an in-
crease in basal [9] or l-arginine–stimulated [10] nitric
oxide synthesis with ACEI or ARB treatment, whereas
others found an increase in renal vascular nitric oxide findings. Twenty-two subjects met all inclusion criteria
synthase activity with ACEI treatment [11, 12]. in the absence of any exclusion criteria. One subject
The current study was designed to further address this withdrew informed consent after the baseline examina-
issue. We examined the effects of a one-week treatment tion, and one subject had to be excluded from the study
with the ACEI enalapril, the ARB eprosartan, and a com- due to a transient increase in liver enzymes that in a
bination of both drugs but with half the dose, on renal more detailed examination was found to be unrelated
hemodynamic parameters. The response of renal plasma to the study medication. Baseline characteristics of the
flow (RPF) to an inhibition of nitric oxide synthase with study participants are given in Table 1.
NG-monomethyl-l-arginine (L-NMMA) was measured
in each study phase, which permitted an assessment of Study design
the contribution of basal nitric oxide synthesis to renal The study protocol was approved by the Clinical Inves-
perfusion in the respective study phases. tigation Ethics Committee of the University of Erlangen-
Nu¨rnberg.
The study consisted of four phases in a randomizedMETHODS
double-blind order: treatment with placebo, enalaprilStudy participants
(20 mg once daily), eprosartan (600 mg once daily), or
Subjects eligible for the study were screened for arte-
a combination of both drugs (enalapril 10 mg and epro-rial hypertension at the campus of the University of Er-
sartan 300 mg, once daily). Each treatment was done forlangen-Nu¨rnberg. Students with a casual blood pressure
seven days and was followed by a two-week washout phase
140 mm Hg (systolic) and/or 90 mm Hg (diastolic),
before the next study phase began. Participants werebut 180 mm Hg (systolic) and 105 mm Hg (diastolic)
asked to take the study medication at a fixed time in theobtained with a standard sphygmomanometer after five
morning. At day seven of each treatment phase, theminutes of rest at three independent occasions were in-
participant was invited to our laboratory at 7:30 a.m.vited to our outpatient clinic for a detailed medical exam-
There, blood pressure was measured (“casual blood pres-ination including history taking, physical examination,
sure” according to WHO criteria), a routine laboratorydirect ophthalmoscopic examination, 12-lead electrocardi-
examination was performed, the participant was inter-ography, routine laboratory examination, and 24-hour
viewed about any side effects of treatment, and he tookurine sampling. Echocardiography, ultrasonography of
his study medication for this day. Then, renal vascularthe kidneys and duplex sonography of the renal arteries
endothelial function testing was performed. Study medi-were performed where indicated. Inclusion criteria were
cation for the next study phase was then handed out tomale gender, age between 18 and 35 years, and essential
the participant. He was instructed to begin the followinghypertension according to the WHO criteria as outlined
treatment phase after 14 days of wash-out phase, whichabove. Exclusion criteria included the presence of any
was chosen as far greater than five times the half-lives ofform of secondary hypertension; any irreversible end-
enalapril (11 hours) and eprosartan (5 to 9 hours). Allorgan damage due to arterial hypertension; any signifi-
analyses of the effects of treatment on hemodynamic pa-cant disease other than mild essential hypertension; a
rameters were made in comparison to the placebo phase.history of antihypertensive drug intake within a period
of three months prior to the study; cigarette smoking
Renal vascular endothelial function testingwithin a period of one year prior to the study; hypercho-
Renal plasma flow (RPF) and glomerular filtration ratelesterolemia (total cholesterol 160 mg/dL).
(GFR) were determined by constant input clearanceAll volunteers gave written informed consent prior to
technique with para-aminohippurate (Nephrotest; Merck,study inclusion. Further treatment of hypertension in
Sharp & Dohme, Hertfordshire, UK) and inulin (Inutest;our outpatient clinic was offered to all subjects screened
Fresenius, Linz, Austria), respectively, as suggested byfor the study, and all of them received a letter to inform
their general practitioner about clinical and laboratory Cole and coworkers [13] and established in our labora-
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Table 2. Effect of treatment on hemodynamic parameters
Parameter Placebo Enalapril Eprosartan Combination
Casual systolic blood pressure mm Hg 1453 1443 1443 1402ad,bd
Casual diastolic blood pressure mm Hg 931 922 941 901ad,ce
Supine systolic blood pressure mm Hg 1343 1282ae 1322bd 1253ae,ce
Supine diastolic blood pressure mm Hg 802 741ae 781bd 722ae,ce
Supine mean arterial pressure mm Hg 962 892ae 942ce 882ae,cd
Heart rate min1 591 621ad 632ae 622
Renal plasma flow mL/min 68931 74640 79748 80238ae
Glomerular filtration rate mL/min 1364 1353 1373 1384
Filtration fraction % 20.50.7 18.90.8 18.10.8ad 17.60.6ae
Renal vascular resistance mm Hg · min1 · mL1 81.34.1 70.13.5ad 68.83.3ad 62.72.7ae,bd,cd
a Significant differences of enalapril, eprosartan, or combination in comparison with placebo
b Significant differences of eprosartan or combination in comparison with enalapril
c Significant differences of combination in comparison with eprosartan
d P  0.05
e P  0.01
tory for many years [14, 15]. In brief, after administration ing GFR by RPF. Renal vascular resistance (RVR) was
of a loading dose, a steady state between infusion and calculated as mean arterial pressure (MAP)  (1  he-
renal excretion of the tracer substances was reached after matocrit)/RPF.
120 minutes. Blood samples for the determination of
Statisticspara-aminohippurate and inulin to assess baseline RPF
and GFR values were drawn at this time and before All statistical analysis was carried out using SPSS soft-
infusion was started. Subsequently, L-NMMA (Clinalfa, ware (release 8.0; SPSS Inc., Chicago, IL, USA). Before
Switzerland) was infused to inhibit endothelial nitric ox- further analysis was performed, a Kolmogorow-Smirnow
ide synthase (3 mg/kg over 5 min, followed by constant test showed that all baseline data and those after each
infusion over 25 min with a rate of 3 mg/h, that is, a total treatment phase had a normal distribution. Analysis of
dose of 4.25 mg/kg). After L-NMMA infusion, another variance (ANOVA) was conducted to analyze differences
blood sample was drawn to measure para-aminohippur- between parameters evoked by study medication, and
ate and inulin, and thus to assess RPF and GFR after the Student t test with an  level corrected for multiple
nitric oxide synthase inhibition. Blood pressure (“supine comparisons was performed for post hoc analyses. The
blood pressure”) was measured with an oscillometric Student t test was used to analyze the effects of L-NMMA
device (Dinamap 1846 SX; Criticon, Norderstedt, Ger- in each study phase. For correlation analysis, Pearson’s
many) in parallel with blood sampling. All participants correlation coefficients were calculated. Comparison of
drank 10 mL/kg of mineral water during the clearance correlation coefficients was performed after the Fisher
studies. z-transformation. A two-tailed P value0.05 was consid-
ered to be significant. All values are expressed as meanLaboratory measurements and calculation of renal
standard error of the mean.hemodynamic parameters
Blood samples were centrifuged immediately at 4	C
and were stored at 21	C until measurement. Measure- RESULTS
ment of para-aminohippurate and inulin was performed Effect of treatment on hemodynamic parameters
after completion of the study with the investigators still
Hemodynamic parameters in the placebo, enalapril,unaware of the order of treatment phases in individual
eprosartan, and combination phase are depicted in Table 2.study participants. Details concerning the measurement
Compared to baseline (143  11/95  6 mm Hg), theof inulin and para-aminohippurate have been published
placebo did not have a significant effect on blood pres-previously [15]. In brief, para-aminohippurate was mea-
sure (145  3/93  1 mm Hg, NS). Compared to thesured by the method of Smith and coworkers [16]; inulin
placebo phase, effects on casual blood pressure were onlywas measured indirectly with an enzymatic method after
found with combination treatment (decrease by 5 2/3conversion to fructose. Each blood sample was measured
1 mm Hg; P  0.05), whereas neither enalapril alonein duplicate with a coefficient of variation of5%. Mea-
(decrease by 2 2/1 2 mm Hg; PNS) nor eprosartansurements with a coefficient of variation of 5% or greater
alone (decrease by 1  1/0  2 mm Hg; P  NS) hadwere excluded from further analysis. Inulin and para-
a significant effect on casual blood pressure.aminohippurate clearances were calculated as a meta-
In the placebo, enalapril, eprosartan, and combinationbolic clearance rate from the serum concentrations and
infusion rates. Filtration fraction was calculated by divid- phases, 17, 16, 17, and 16 sets of renal hemodynamic data
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Table 3. Effect of L-NMMA on hemodynamic parameters
Parameter Placebo Enalapril Eprosartan Combination
Change of mean arterial pressure mm Hg 52a 42a 51b 42a
Change of heart rate min1 31a 31a 41c 41b
Change of renal plasma flow mL/min 10131b 14337a 16141b 16038b
Change of glomerular filtration rate mL/min 72a 154a 72c 63
Change of filtration fraction % 31b 31b 41c 51c
Change of renal vascular resistance mm Hg · min · L1 144b 144b 183c 173c
Changes of hemodynamic parameters after administration of L-NMMA compared with baseline parameters. Blood pressure was measured with the participant
in the supine position.
a P  0.05, b P  0.01, c P  0.001, significant effects of L-NMMA compared with baseline parameters
were available for analysis, respectively. RPF increased sartan treatment on RPF, correlations between the in-
with combination treatment by 123  36 mL/min (P  crease in RPF compared to the placebo phase and the
0.01). No significant changes of RPF compared to the response of RPF to L-NMMA were calculated for the
placebo phase were observed with enalapril alone (in- respective treatment phases. In the enalapril phase, there
crease by 59  46 mL/min, P  0.21) and eprosartan was no significant correlation between the increase in
alone (increase by 113 51 mL/min, P 0.06). GFR was RPF by enalapril and the L-NMMA–induced decrease in
not affected by any treatment. There were no significant RPF (r0.44, P 0.10). In contrast, highly significant
correlations between changes in blood pressure and correlations between the effects of treatment and the
changes in renal hemodynamics in each study phase response of RPF to L-NMMA were found in the eprosar-
(data not shown). tan (r  0.86, P  0.001) and combination phases (r 
Compared to the placebo phase (81.3  4.1 mm Hg · 0.70, P 0.01), with these correlations not being statis-
min · L1), RVR was reduced by each treatment (enala- tically different (Fig. 1). The greater basal nitric oxide
pril, 70.1  3.4 mm Hg · min · L1; eprosartan, 68.8  synthesis and release in the renal vasculature (that is,
3.1 mm Hg · min · L1; all P  0.05 vs. placebo), with the greater the vasoconstriction), the more marked was
the most prominent effect observed in the combination the increase in RPF after one week of treatment.
phase (62.7  2.7 mm Hg · min · L1; P  0.001 vs.
placebo, and P  0.05 vs. each monotherapy).
DISCUSSION
Effect of L-NMMA on hemodynamic parameters The present study examined the effects of a series of
Administration of L-NMMA caused an increase in one-week treatments with the ACEI, enalapril, and the
blood pressure, a decrease in heart rate, a decrease in ARB, eprosartan, alone or in combination on renal he-
RPF, and an increase in GFR in the placebo phase (Ta- modynamic parameters. Neither substance alone had a
ble 3). The response of hemodynamic parameters to the clear-cut effect on RPF over the observation period,
L-NMMA infusion was similar in the active treatment whereas an increase in RPF was found with the combina-
phases, although some changes did not reach our pre- tion therapy. Similarly, RVR was more reduced with the
fixed level of significance. However, L-NMMA caused combination therapy than with enalapril or eprosartan
a significant decrease in RPF in all study phases. therapy alone.
Pair-wise comparison of the effects of L-NMMA One week of treatment with eprosartan alone did not
across all treatment and placebo phases revealed no sta-
significantly reduce blood pressure. The absence of a
tistically significant differences. For example, increases
blood pressure lowering effect after short-term treat-in mean arterial pressure induced by L-NMMA (5 
ment with an ARB is not uncommon, as the response2 mm Hg, 4  2 mm Hg, 5  1 mm Hg, and 4  2
rate of blood pressure has been found greater after 26mm Hg) were similar in the placebo, enalapril, eprosar-
weeks than after 12 weeks of treatment with eprosartantan, and combination phases, respectively (Table 3).
[17]. Our data indicate an effect of eprosartan on renalHowever, although not statistically significant, numeri-
hemodynamics that is independent of blood pressure.cally the percent decrease in RPF induced by L-NMMA
However, the effects of enalapril and combination ther-seemed to be greater in the combination and eprosartan
apy on renal hemodynamics also were independent ofphases than in the enalapril and placebo phases (16 
blood pressure changes, as shown by the lack of signifi-4%, 17  3%, 11  4%, and 12  4%, respectively).
cant correlations between blood pressure changes and
Contribution of the renal vascular nitric oxide system changes in RPF and GFR.
to the effects of treatment on RPF We observed a trend toward an increase of RPF after
the one-week treatment with eprosartan alone (P To examine whether the renal vascular nitric oxide
system contributes to the effects of enalapril and/or epro- 0.06). This principal effect of eprosartan on RPF in our
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both GFR and RPF and both RPF and MAP, respec-
tively, evoked by the study drugs. In accordance with
the study of Schmitt and coworkers [19], we found a
decrease in filtration fraction with combination therapy
(and, in addition, with eprosartan alone), and a decrease
in RVR in every active treatment phase.
In contrast to therapy with either enalapril or eprosar-
tan alone, our study results show a clear-cut effect of
the combination therapy on RPF even after a relatively
short treatment period. This finding supports data from
other investigators who found additive effects of such
combination therapy in heart failure [7, 8] and protein-
uria (abstract; Russo D, J Am Soc Nephrol 11:76A, 2000;
abstract; Kincaid-Smith PS, J Am Soc Nephrol 11:349A,
2000) that were independent of blood pressure. The
mechanism of these additive effects is not yet clear, al-
though theoretical considerations and experimental data
help explain them [22]. The different sites of action of
ARB and ACEI cause a complete blockade of angioten-
sin II effects combined with enhanced bradykinin pro-
duction. Thereby, nitric oxide bioavailability is increased
directly via AT2-receptor stimulation and indirectly via
bradykinin [3, 5]. Of note, we did not add an ARB on
top of maximum dose ACEI, but instead used half the
dose of both substances. Nevertheless, a clear-cut effect
on casual blood pressure, RPF, and RVR was found
in the combination phase, but not in phases with the
maximum recommended dose of enalapril and eprosar-
tan alone. We are convinced that this finding also sug-
gests a specific effect of combining two therapeutic prin-
ciples and is not the mere result of elevated tissue
concentrations of drugs interfering with the actions of
angiotensin II.
From in vitro experiments and animal models, an im-
provement of renal vascular endothelial function is be-
lieved to play a role in the effects of ARB, but also of
ACEI, on renal hemodynamics [2]. However, experi-
mental data in humans do not uniformly show a stimula-
Fig. 1. Contribution of the renal vascular nitric oxide system to the tion of the renal vascular nitric oxide system after treat-
effects of treatment on renal plasma flow. The response of renal plasma
ment with ARB or ACEI. Likewise, Dijkhorst-Oei et alflow (RPF) on inhibition of nitric oxide with NG-monomethyl-l-arginine
did not find an improvement of renal vascular endothe-(L-NMMA; that is, the change in RPF) in the respective study phases
is shown on the x-axis. Changes of basal RPF with enalapril, eprosartan, lial function with enalapril treatment in hypertensive
and combination therapy are shown on the y-axis of panels A (r 
patients [9], and Komers et al found the same result with0.44, P  NS), B (r  0.86, P  0.001), and C (r  0.70, P 
ramipril and losartan in healthy subjects [10]. In contrast,0.002), respectively.
Higashi et al found an improvement of renal vascular
endothelial function with the ACEI imidapril in hyper-
tensive patients [11], a result also found by Mimran et
study is in accordance with data from other investigators al in patients treated with an ACEI for more than two
who also found an increase in RPF after treatment with years [12]. Some of these discrepancies can be explained
several ARB drugs as well as with ACEI [10, 11, 18–21]. by pharmacological differences between the study drugs
Similarly, other investigators have found non-significant and by differences between the study cohorts. Also, dif-
effects of ACEI and ARB on GFR [10, 18–21]. Other ferent treatment periods ranging from three [9, 10] and
parameters such as filtration fraction and RVR might over 12 weeks [11], to more than two years [12] might
be superior to estimate the effects of ACEI and ARB have effects on the results reported here and by other
investigators. Our relatively short treatment period ofon renal hemodynamics, since they integrate changes in
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one week was chosen according to data from experiments through the study medication. However, keeping in mind
that there is an individually different response of RPFwith ACEI indicating that an effect on endothelial dys-
function exists in other vasculatures even after short to the study medication between study participants, one
is forced to use another approach to analyze the effecttreatment periods [reviewed in 23], and to reduce any
potential harm due to the combination therapy, which of L-NMMA on renal vascular tone.
Therefore, we calculated the correlation coefficientswas and still is not established in subjects with mild
essential hypertension who are otherwise healthy. An- between the response of RPF to nitric oxide synthase
inhibition with L-NMMA after seven days of treatmentother factor for the different results found in this and
other studies might play an important role: to date there and the increase in RPF with a particular treatment (ena-
lapril, eprosartan, or combination). Thus, our study usedis no consensus on how to measure or how to define
renal vascular endothelial function in humans. a more sensitive tool to focus more on the individual
subject’s reaction on both changes of RPF due to theThe “golden standard” to examine endothelium-depen-
dent vasodilation, that is, the administration of endothe- study medication and to L-NMMA–induced vasocon-
striction during the respective medication. With this ap-lium-dependent vasodilators such as acetylcholine, is as-
sociated with a considerable risk for study participants proach, significant correlations were found between the
increase in RPF through the study medication and thewhen the renal vasculature must be examined, since a
renal artery catheter has to be invasively inserted [24]. response of RPF to L-NMMA (as a measure of basal
nitric oxide production and release) in the eprosartanTherefore, non-invasive methods have been developed
to examine renal vascular endothelial function including and combination phases, but not in the enalapril phase.
In other words, the improvement of RPF by eprosartansystemic administration of l-arginine, the substrate for
nitric oxide synthesis, and L-NMMA, a competitive in- alone or in combination with enalapril is at least in part
nitric oxide-dependent, whereas this is not the case tohibitor of endothelial nitric oxide synthase. However,
while some authors directly interpret changes of renal the same extent for enalapril. This interpretation is sup-
ported by the equality of the correlation coefficients inhemodynamics in response to l-arginine or L-NMMA as
endothelium-dependent vasodilation or vasoconstriction, the eprosartan and combination phases.
Our study has several limitations. First, oral salt intakerespectively [9, 12], other authors in addition measure
changes of plasma and urinary concentrations of nitrite is a factor known to influence renal hemodynamics con-
siderably [30], and our study participants were not keptand nitrate or urinary cyclic guanosine 3
,5
-monophos-
phate concentration as indicators of nitric oxide activity on a metabolic ward for strictly controlling sodium intake
by a standardized diet. However, they were advised toto conclude about changes of renal vascular endothelial
function [8, 11]. However, these parameters should be maintain their usual diet throughout the whole study
period to reduce the probability that sodium intakeinterpreted cautiously, since nitrate and nitrite might
derive from vasculatures other than the renal vascula- changed during study periods. Besides, the relatively
high salt intake that is common in Bavaria to some extentture, and cyclic guanosine 3
,5
-monophosphate also
serves as a second messenger for atrial natriuretic pep- might be responsible for the relatively low blood pres-
sure changes with ACEI and ARB treatment in ourtide and does not specifically reflect nitric oxide activity.
Thus, while such parameters are helpful for the assess- study participants [31]. Second, fluid load during a clear-
ance study can influence renal hemodynamics markedlyment of nitric oxide-dependent vasodilation, in analyzing
endothelial function of the renal vasculature they cannot [32]. Therefore, the same well-defined volume was ad-
ministered to our study participants at each examination.substitute for direct measurement of RPF in response
to inhibition (or stimulation) of nitric oxide synthase. Third, differences in the time-course of drug action might
be responsible for different effects on renal hemodynam-In our laboratory, we have established the administra-
tion of l-arginine (100 mg/kg) and L-NMMA (total dose, ics. For eprosartan, a once-daily dosage has been found
to be as effective as a twice-daily dosage [33]. For enala-4.25 mg/kg) to analyze renal vascular endothelial func-
tion [25–27]. For the present study we chose to administer pril, different responses of renal hemodynamics have
been found 4, 12, and 24 hours after drug intake [20].L-NMMA, since we expected that both enalapril and epro-
sartan would increase basal nitric oxide synthesis [3, 5]. We decided to advise our participants to take their study
medication for day 7 immediately before the para-amino-In fact, there was an increase in RPF compared to base-
line values with eprosartan therapy, whereas changes of hippurate and inulin infusions were started, so that ex-
actly the same time interval between drug intake andRPF with enalapril alone and eprosartan alone were
not statistically significant. Administration of L-NMMA administration of L-NMMA in all study participants
could be guaranteed.decreased RPF in all study phases including the placebo
phase by about the same percentage. These results are In conclusion, a one-week treatment with the com-
bined eprosartan/enalapril therapy given at half the dosein accordance with two other studies [28, 29], and, at
first glance, rule out any change in endothelial function of each drug increases RPF via a nitric oxide-dependent
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ment of renal function without urine collection. A critical evalua-mechanism. Enalapril administered alone had no effect
tion of the constant-infusion-technique for determination of inulin
on renal vascular endothelial function nor did it increase and para-aminohippurate. N Engl J Med 287:1109–1114, 1972
14. Jacobi J, Schlaich MP, Delles C, et al: Angiotensin II stimulatesRPF. Although the one-week treatment with eprosartan
left ventricular hypertrophy in hypertensive patients independentlyalone had no clear-cut effect on RPF, this substance
of blood pressure. Am J Hypertens 12:418–422, 1999
appears to increase nitric oxide bioavailability in the 15. Schmieder RE, Veelken R, Schobel HP, et al: Glomerular hyper-
filtration during sympathetic nervous system activation in earlyrenal vasculature.
essential hypertension. J Am Soc Nephrol 8:893–900, 1997
16. Smith HW, Finkelstern N, Aliminosa L, et al: The renal clearance
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